Merck Serono, a division of Merck KGaA, has received marketing authorization from the European Commission for Kuvan for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients. Kuvan, which had previously received Orphan Medicinal Product designation from the European Medicines Evaluation Agency (EMEA), is the first drug approved in Europe for HPA due to PKU or BH4 deficiency. “To date, there has been no drug treatment available in Europe for pati...